起立性低血圧症治療薬の世界市場2019-2023

◆英語タイトル:Orthostatic Hypotension Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR31811
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年8月26日
◆ページ数:123
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、起立性低血圧症治療薬の世界市場について調べ、起立性低血圧症治療薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、起立性低血圧症治療薬の市場規模をセグメンテーション別(製品別(ミドドリン、ノーセラ(ドロキシドパ)、フルドロコルチゾン、他の薬)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は起立性低血圧症治療薬の世界市場規模が2019-2023期間中に年平均8%成長すると予測しています。
・サマリー
・レポートの範囲
・起立性低血圧症治療薬の市場状況
・起立性低血圧症治療薬の市場規模
・起立性低血圧症治療薬の市場予測
・起立性低血圧症治療薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(ミドドリン、ノーセラ(ドロキシドパ)、フルドロコルチゾン、他の薬)
・起立性低血圧症治療薬の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Orthostatic Hypotension Drugs Market 2019-2023: About the Market
Orthostatic hypotension is the reduction in systolic blood pressure and can be divided into neurogenic and non-neurogenic forms. Technavio’s orthostatic hypotension drugs market analysis considers sale from midodrine, northera (droxidopa), fludrocortisone, and other drugs. Our analysis also considers the orthostatic hypotension drugs market in Asia, Europe, North America, and ROW. In 2018, the midodrine segment had a significant share. However, the Northera (droxidopa) segment will grow faster and emerge as the market leader by the end of the forecast period. Northera can activate alpha 1 adrenergic receptors and have numerous physiological effects that may ameliorate the symptoms of nOH. This will contribute to the demand for Northera over the forecast period. Also, our global orthostatic hypotension drugs market report looks at factors such as increasing prevalence of OH in geriatric population, increasing prevalence of chronic diseases associated with high risk of OH, and high market growth opportunities for OH drugs in emerging countries. However, the uncertainties in low diagnosis rate, lack of clinical evidence and unfavorable safety profile of OH drugs, and adoption of non-pharmacological treatment options as first line therapy may hamper the growth of orthostatic hypotension drugs market over the forecast period.

Global Orthostatic Hypotension Drugs Market: Overview

Increasing prevalence of chronic diseases associated with high risk of OH
The prevalence of the neurodegenerative diseases, cardiovascular diseases and diabetes is significantly increasing worldwide, raising the risk of OH. It is associated with an underlying autonomic neurologic disorder. Dehydration is also a common condition in people which increases the risk of OH and causing damage to the nerves. This increase in prevalence of chronic diseases associated with high risk of OH will lead to the expansion of the global orthostatic hypotension drugs market at a CAGR of almost 8% during the forecast period.

Rise in the use of combination therapy in OH treatment
OH, is a chronic debilitating illness that is difficult to treat in several patients. Single drug therapy might not be adequate in treating OH patients as orthostatic stress varies with circumstances during the day. This has led to the increasing focus on the use of combination therapy in OH treatment. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global orthostatic hypotension drugs market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, global orthostatic hypotension drugs market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several orthostatic hypotension drugs manufacturers, that include Amneal Pharmaceuticals Inc., H. Lundbeck AS, Mylan NV, Novartis AG, Pfizer Inc.

Also, orthostatic hypotension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: Executive Summary
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Midodrine – Market size and forecast 2018-2023
• Northera (droxidopa) – Market size and forecast 2018-2023
• Fludrocortisone – Market size and forecast 2018-2023
• Other drugs – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• R&D of new drugs for OH treatment
• Use of combination therapy in OH treatment
• Adoption of fludrocortisone as off-label first-line pharmacotherapy
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amneal Pharmaceuticals Inc.
• H. Lundbeck AS
• Mylan NV
• Novartis AG
• Pfizer Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Midodrine – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Midodrine – Year-over-year growth 2019-2023 (%)
Exhibit 22: Northera (droxidopa) – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Northera (droxidopa) – Year-over-year growth 2019-2023 (%)
Exhibit 24: Fludrocortisone – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Fludrocortisone – Year-over-year growth 2019-2023 (%)
Exhibit 26: Other drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Other drugs – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America – Year-over-year growth 2019-2023 (%)
Exhibit 34: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Amneal Pharmaceuticals Inc. – Vendor overview
Exhibit 49: Amneal Pharmaceuticals Inc. – Business segments
Exhibit 50: Amneal Pharmaceuticals Inc. – Organizational developments
Exhibit 51: Amneal Pharmaceuticals Inc. – Segment focus
Exhibit 52: Amneal Pharmaceuticals Inc. – Key offerings
Exhibit 53: H. Lundbeck AS – Vendor overview
Exhibit 54: H. Lundbeck AS – Business segments
Exhibit 55: H. Lundbeck AS – Organizational developments
Exhibit 56: H. Lundbeck AS – Geographic focus
Exhibit 57: H. Lundbeck AS – Key offerings
Exhibit 58: Mylan NV – Vendor overview
Exhibit 59: Mylan NV – Product segments
Exhibit 60: Mylan NV – Organizational developments
Exhibit 61: Mylan NV – Geographic focus
Exhibit 62: Mylan NV – Segment focus
Exhibit 63: Mylan NV – Key offerings
Exhibit 64: Novartis AG – Vendor overview
Exhibit 65: Novartis AG – Business segments
Exhibit 66: Novartis AG – Organizational developments
Exhibit 67: Novartis AG – Geographic focus
Exhibit 68: Novartis AG – Segment focus
Exhibit 69: Novartis AG – Key offerings
Exhibit 70: Pfizer Inc. – Vendor overview
Exhibit 71: Pfizer Inc. – Business segments
Exhibit 72: Pfizer Inc. – Organizational developments
Exhibit 73: Pfizer Inc. – Geographic focus
Exhibit 74: Pfizer Inc. – Segment focus
Exhibit 75: Pfizer Inc. – Key offerings
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: Definition of market positioning of vendors



【掲載企業】

Amneal Pharmaceuticals Inc., H. Lundbeck AS, Mylan NV, Novartis AG, and Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[起立性低血圧症治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆